Estradiol dibutyrate (EDBu), or estradiol dibutanoate, is an estrogen medication and an estrogen ester – specifically, a diester of estradiol – which is no longer used.[1][2] It was a component of Triormon Depositum, a combination formulation of estradiol dibutyrate, testosterone caproate, and hydroxyprogesterone heptanoate which was developed in the 1950s.[2]
Clinical data | |
---|---|
Other names | EDBu; Estradiol dibutanoate; Estradiol 3,17β-dibutanoate |
Routes of administration | Intramuscular injection |
Drug class | Estrogen; Estrogen ester |
Identifiers | |
CAS Number | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.057.990 |
Chemical and physical data | |
Formula | C26H36O4 |
Molar mass | 412.570 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Cacciari P (August 1960). "[Experimental research on estradiol dibutyrate]". Minerva Ginecol (in Italian). 12: 788–9. PMID 13689684.
- ^ a b Ermiglia G, Valli P (1957). "Triormon depositum in climacteric syndrome. Curves of excretion of catabolites and duration of the therapeutic effect". Quaderni Clin. Ostet. E Ginecol. 12: 284–93.
Triormon depositum (estradiol dibutyrate 3, testosterone caprylate 50, and hydroxyprogesterone heptanoate 30 mg.), administered in castor oil-benzyl benzoate soln. or polyvinylpyrrolidone suspension to 21 women in climacteric, was followed by estradiol, pregnanediol, and 17-keto steroid urinary curves, most with a peak at the 4th day, and approaching starting values at the 8-10th day. The therapeutic efficacy of the drug was satisfactory.